QL Biopharm
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $72.9M
Overview
An oncology biotech developing novel multispecific antibody drugs to treat resistant cancers.
Oncology
Technology Platform
An antibody engineering platform for the design and development of novel multispecific antibodies that engage multiple targets to enhance anti-tumor activity.
Funding History
1Total raised:$72.9M
Series C$72.9M
Opportunities
Opportunity to address significant unmet need in oncology by creating drugs that overcome resistance mechanisms through multi-target engagement.
Risk Factors
Clinical risk that complex multispecific antibodies may not show improved efficacy or may have unexpected toxicities compared to simpler agents.
Competitive Landscape
Faces intense competition in the multispecific antibody space from giants like Roche and Regeneron, as well as numerous biotech peers.